RPL-554 (LS-193,855) is a drug candidate for respiratory diseases. It is an analog of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3; indeed, it is >3000-times more potent against PDE3 than PDE4. As of October 2015, inhaled RPL-554 delivered via a nebulizer was in development for COPD and had been studied in asthma. PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect.
Attributes | Values |
---|---|
rdf:type |
|
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
c |
|
CAS number |
|
CAS supplemental |
|
ChemSpiderID |
|
H |
|
IUPAC name |
|
n |
|
O |
|
PubChem |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
UNII |
|
verifiedrevid |
|
width |
|
has abstract |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
FDA UNII code |
|
PubChem |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of |